vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Axos Financial, Inc. is the larger business by last-quarter revenue ($392.2M vs $281.3M, roughly 1.4× Guardant Health, Inc.). Axos Financial, Inc. runs the higher net margin — 31.8% vs -45.7%, a 77.5% gap on every dollar of revenue. Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 16.1%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
AX vs GH — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $281.3M |
| Net Profit | $124.7M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | -43.0% |
| Net Margin | 31.8% | -45.7% |
| Revenue YoY | — | 39.4% |
| Net Profit YoY | 18.5% | -15.8% |
| EPS (diluted) | $2.15 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $281.3M | ||
| Q3 25 | $323.4M | $265.2M | ||
| Q2 25 | $321.4M | $232.1M | ||
| Q1 25 | $308.8M | $203.5M | ||
| Q4 24 | $307.9M | $201.8M | ||
| Q3 24 | $320.7M | $191.5M | ||
| Q2 24 | $290.9M | $177.2M |
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $-128.5M | ||
| Q3 25 | $112.4M | $-92.7M | ||
| Q2 25 | $110.7M | $-99.9M | ||
| Q1 25 | $105.2M | $-95.2M | ||
| Q4 24 | $104.7M | $-111.0M | ||
| Q3 24 | $112.3M | $-107.8M | ||
| Q2 24 | $104.9M | $-102.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | -43.0% | ||
| Q3 25 | 46.3% | -37.3% | ||
| Q2 25 | 48.5% | -45.9% | ||
| Q1 25 | 47.9% | -54.6% | ||
| Q4 24 | 48.8% | -62.4% | ||
| Q3 24 | 49.6% | -61.3% | ||
| Q2 24 | 49.6% | -56.8% |
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | -45.7% | ||
| Q3 25 | 34.7% | -35.0% | ||
| Q2 25 | 34.4% | -43.0% | ||
| Q1 25 | 34.1% | -46.8% | ||
| Q4 24 | 34.0% | -55.0% | ||
| Q3 24 | 35.0% | -56.3% | ||
| Q2 24 | 36.0% | -57.9% |
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $-1.01 | ||
| Q3 25 | $1.94 | $-0.74 | ||
| Q2 25 | $1.89 | $-0.80 | ||
| Q1 25 | $1.81 | $-0.77 | ||
| Q4 24 | $1.80 | $-0.90 | ||
| Q3 24 | $1.93 | $-0.88 | ||
| Q2 24 | $1.75 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $3.1B | $-99.3M |
| Total Assets | $29.2B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $378.2M | ||
| Q3 25 | $2.6B | $580.0M | ||
| Q2 25 | $1.9B | $629.1M | ||
| Q1 25 | $2.0B | $698.6M | ||
| Q4 24 | $2.4B | $525.5M | ||
| Q3 24 | $2.6B | $585.0M | ||
| Q2 24 | $2.0B | $933.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $312.7M | $1.1B | ||
| Q1 25 | $377.4M | $1.1B | ||
| Q4 24 | $358.7M | $1.1B | ||
| Q3 24 | $313.5M | — | ||
| Q2 24 | $325.7M | — |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $-99.3M | ||
| Q3 25 | $2.8B | $-354.5M | ||
| Q2 25 | $2.7B | $-305.5M | ||
| Q1 25 | $2.6B | $-250.8M | ||
| Q4 24 | $2.5B | $-139.6M | ||
| Q3 24 | $2.4B | $-60.1M | ||
| Q2 24 | $2.3B | $-1.6M |
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $2.0B | ||
| Q3 25 | $27.4B | $1.3B | ||
| Q2 25 | $24.8B | $1.3B | ||
| Q1 25 | $24.0B | $1.3B | ||
| Q4 24 | $23.7B | $1.5B | ||
| Q3 24 | $23.6B | $1.5B | ||
| Q2 24 | $22.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $-26.4M | ||
| Q3 25 | $118.4M | $-35.4M | ||
| Q2 25 | $490.3M | $-60.3M | ||
| Q1 25 | $73.7M | $-62.7M | ||
| Q4 24 | $162.5M | $-64.5M | ||
| Q3 24 | $70.8M | $-51.1M | ||
| Q2 24 | $305.5M | $-94.0M |
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | $-54.2M | ||
| Q3 25 | $109.3M | $-45.8M | ||
| Q2 25 | $436.1M | $-65.9M | ||
| Q1 25 | $65.1M | $-67.1M | ||
| Q4 24 | $156.4M | $-83.4M | ||
| Q3 24 | $53.0M | $-55.3M | ||
| Q2 24 | $269.5M | $-99.1M |
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | -19.3% | ||
| Q3 25 | 33.8% | -17.3% | ||
| Q2 25 | 135.7% | -28.4% | ||
| Q1 25 | 21.1% | -33.0% | ||
| Q4 24 | 50.8% | -41.3% | ||
| Q3 24 | 16.5% | -28.9% | ||
| Q2 24 | 92.6% | -55.9% |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 9.9% | ||
| Q3 25 | 2.8% | 3.9% | ||
| Q2 25 | 16.9% | 2.4% | ||
| Q1 25 | 2.8% | 2.2% | ||
| Q4 24 | 2.0% | 9.4% | ||
| Q3 24 | 5.5% | 2.2% | ||
| Q2 24 | 12.4% | 2.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 4.43× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 1.55× | — | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | 2.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
